Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | C1R | P00736 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12066583 | 0.89 | MLKL (0.46) | LMNAKDM4EALDH1A1MAPTOPRM1 | |
| SCHEMBL14770549 | 0.83 | ALDH1A1 (0.42) | LMNAKDM4EALDH1A1MAPTHTT | |
| SCHEMBL14770550 | 0.78 | FLT3 (0.40) | LMNAKDM4E | |
| SCHEMBL14770492 | 0.78 | AMY1A (0.41) | LMNAKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL14770613 | 0.78 | FLT3 (0.40) | LMNAKDM4EALDH1A1MAPTHTT | |
| SCHEMBL14774196 | 0.78 | MLKL (0.42) | LMNAKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL14770646 | 0.76 | SCN10A (0.40) | LMNAKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL14770535 | 0.76 | MEN1 (0.53) | LMNAKDM4EALDH1A1MAPTHTT | |
| SCHEMBL14770638 | 0.75 | SCN10A (0.52) | LMNAKDM4E | |
| SCHEMBL14770640 | 0.75 | SCN10A (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | LMNA 4407/4885KDM4E 4045/4885ALDH1A1 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.